Comparison of MOG and AQP4 antibody seroprevalence in Korean adults with inflammatory demyelinating CNS diseases
Jae‐Won Hyun(Seoul National University Hospital), Ho Jin Kim(National Cancer Center), Hyejung Lee(Korea University Medical Center), Kyong Jin Shin(Inje University Haeundae Paik Hospital), Sang‐Soo Lee(Hallym University), Ha Young Shin(Yonsei University), Tai‐Seung Nam(Chonnam National University Hospital), Seol‐Hee Baek(Korea University Medical Center), Woojun Kim(National Cancer Center), Jin Myoung Seok(Samsung Medical Center), Ohyun Kwon(Eulji University), Jong Seok Bae(Hallym University), Byung‐Jo Kim(Korea University), Eun Hee Sohn(Chungnam National University), Sa‐Yoon Kang(Jeju National University), So‐Young Huh(Kosin University Gospel Hospital), Jong Kuk Kim(Dong-A University), Joong‐Yang Cho(Inje University Ilsan Paik Hospital), Seong‐il Oh(Kyung Hee University), Yoon‐Ho Hong(Seoul Metropolitan Government), Jeeyoung Oh(Université Paris-Sud), Young‐Min Lim(Ulsan College), Suk Geun Han(Samsung Medical Center), Jong Hwa Shin(Samsung Medical Center), Seung‐Han Lee(Chonnam National University Hospital), Sun‐Young Kim(Hanyang Cyber University), Hyunjin Kim(Samsung Medical Center), Su‐Hyun Kim(National Cancer Center), Min Young Lee(National Cancer Center), So Yeon Kim(Ulsan College), Seung Woo Kim(Ulsan College), Yeseul Kim(National Cancer Center), Sun‐Young Oh(Inje University Busan Paik Hospital), Hye Lim Lee(Korea University Medical Center), Ju‐Hong Min(Samsung Medical Center), Woo Kyo Jeong(Sungkyunkwan University), Byoung Joon Kim(Samsung Medical Center), Hyun-June Shin(Yonsei University), Eun Bin Cho(Changwon National University)
Cited by 14
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
|Journal of Neuroinflammation|2018|740
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
|The Lancet|2019|722
Neuromyelitis optica
|Nature Reviews Disease Primers|2020|464
Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder
|Multiple Sclerosis Journal|2011|284